NL-OMON44449
Completed
Not Applicable
First attempt success ratio of intravenous cannulation with the Veinplicity® - Veinplicity
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- intraveneuze toegang, perifeer
- Sponsor
- Catharina-ziekenhuis
- Enrollment
- 125
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •In order to be eligible to participate in this study, a patient must meet all of the following criteria:
- •\* Patients must be in the age of 18 years or older;
- •\* Patients with a medium risk profile on the A\-DIVA scale (score 2 or 3\);
- •\* Patients must be conscious and be able to adequately answer questions.
Exclusion Criteria
- •A potential patient who meets any of the following criteria will be excluded from participation in this study:
- •\* Patients in which an intravenous catheter is already inserted on the ward;
- •\* Patients with medical devices in the body (pacemaker, ICD, trans\-cerebral electrode placement, electrode placement that applies current to the carotid sinus region, other neurostimulators);
- •\* Patients who do not understand questions or generate adequate data, due to physical or communicational disorders.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
First attempt success ratio of intravenous cannulation with the Veinplicity®Difficult intravenous access, unsuccessful attempt to insert a peripheral intravenous catheter.NL-OMON24775Catharina HospitalDepartment of anesthesiology, intensive care and pain medicineMichelangelolaan 25623 EJ Eindhoven125
Not yet recruiting
Not Applicable
comparison of ultrasound guided needle insertion success vs landmark guided in percutaneous tracheostomyHealth Condition 1: J00-J99- Diseases of the respiratory systemCTRI/2021/02/031580Sangeeta Chakraborty
Not yet recruiting
Phase 1
Mesenchymal Stem Cell Therapy For Covid 19Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/08/027043eurogen Brain and Spine Institute
Recruiting
Phase 1
A Phase-I clinical study of intravenous AntiPlatelet, AntiCoagulant (APAC) in healthy subjects.CTRI/2023/04/051500Cadila Pharmaceutical Limited
Completed
Not Applicable
Phase1 clinical study of a single intravenous dose of TRM-1106 in healthy Japanese adult meJPRN-UMIN000005914Terumo Corporation30